Clinical trials: Lymphatic System Neoplasm
Waldenstrom Macroglobulinaemia, Peripheral Neuropathies
This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process
Neuropathy severely reduces patients' quality of life due to sensory loss, chronic neuropathic pain, and loss of mobility of arms and legs.
- Trial name
- NCT07160270
- Where
- Denmark
- Volunteers
- 90 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood
A Study Of Panobinostat In Children With Refractory Hematologic Malignancies
This study is for patients with relapsed or refractory Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Hodgkin's Disease (HD) or Non-Hodgkin's Lymphoma (NHL).
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Trial name
- NCT01321346
- Testing
- Panobinostat, Cytarabine
- Where
- 20 sites in United States
- Volunteers
- 30 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
Liver Decompensation, Hepatocellular Carcinoma
The Second Multicenter Hemophilia Cohort Study
The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV).
- Conditions
- Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT00341705
- Where
- 48 sites in United States, Brazil and 6 more
- Volunteers
- 2,565 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Cohort Construction and Prognostic Model Construction for Multiple Myeloma
Multiple myeloma (MM) is a disease caused by malignant plasma cell proliferation disorder. Survival outcomes continue to vary widely even within uniformly treated clinical trial populations.
- Trial name
- NCT06366802
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of BCMA-CD19 cCAR in patients with relapsed and/or refractory multiple myeloma and plasmacytoid lymphoma.
- Conditions
- Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Plasmacytoid; Lymphoma
- Trial name
- NCT04162353
- Testing
- BCMA-CD19 cCAR T cells
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- iCell Gene Therapeutics
Childhood Cancer
Inattention in Childhood Cancer Survivors
Specific Aim 1: To assess the feasibility and acceptability of a home-based, computerized cognitive training program with survivors of central nervous system-impacting pediatric cancer (e.g.
- Trial name
- TRICCS (NCT00636337)
- Testing
- Attention Training
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Duke University
Acute Lymphoblastic Leukemia
LAL-BR/2001: Study Treatment to Low Risk ALL
The purpose of this study is increase the efficacy of consolidation (C1) after an intensification phase with high dose of methotrexate, applying analysis of minimal residual disease
- Trial name
- NCT00526175
- Testing
- Prednisone, Vincristine, Daunorubicin
- Where
- 25 sites in Spain
- Volunteers
- 150 people
- Sponsor
- PETHEMA Foundation
Lymphoma
The Value of Monitoring Circulating Cell DNA (ctDNA) in Pediatric Lymphoma: A Prospective, Multicenter Clinical Study
The next-generation sequencing (NGS) based on liquid biopsy has been an emerging technology to identify tumor-specific genetic aberrations in malignant tumors.
- Trial name
- NCT04957901
- Testing
- Pediatric lymphoma protocol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
Leukemia, Acute Lymphoblastic, Leukemia
Vincristine PK and PD in the AYA Population Compared to Younger Children
The trial is to determine if a difference exists in the way that adolescents and young adults metabolize the chemotherapy agent vincristine compared to younger children.
- Trial name
- NCT02360930
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital Los Angeles
Fragile X Syndrome, Angelman Syndrome
Parent and Infant Inter(X)Action Intervention (PIXI)
The objective is to develop and test, through an iterative process, an intervention to address and support the development of infants with a confirmed diagnosis of a neurogenetic disorder with associated developmental delays or…
- Conditions
- Fragile X Syndrome, Angelman Syndrome, Prader-Willi Syndrome, Dup15Q Syndrome
- Trial name
- NCT03836300
- Testing
- Parent-Infant Inter(X)action Intervention (PIXI)
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- RTI International
Chronic Lymphocytic Leukemia
Polymorphism of ITGA4 Gene in Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is a clonal lymphoproliferative disorder that is characterized by heterogeneous presentation at the clinical and molecular levels.
- Trial name
- NCT05371392
- Where
- Egypt
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Sohag University
Recurrent B Acute Lymphoblastic Leukemia
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement…
- Trial name
- NCT02101853
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab
- Where
- 186 sites in United States, Australia and 3 more
- Volunteers
- 669 people
- Sponsor
- National Cancer Institute (NCI)
Acute Leukemia, Acute Lymphoblastic Leukemia
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
Mortality in case of SARS-CoV-2 infection (Covid-19) during acute leukemia (AL) treatment is around 30%, i.e. more than 10 times the one of general population. Severe forms are reported in children receiving chemotherapy for AL.
- Conditions
- Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- PACIFIC (NCT04969601)
- Testing
- vaccine COMIRNATY® (BNT162b2)
- Where
- 2 sites in France
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Acute Lymphoblastic Leukemia
Assesment of JL1 Expression in Acute Leukemia
The aim of this study is to assess JL1 expression by flow cytometric immunophenotyping in patients with B-cell Acute Lymphoblastic Leukemia (ALL) and to correlate it with clinical, morphological, immunophenotypic, cytogenetic…
- Trial name
- NCT04554381
- Testing
- JL1 antigen
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Hodgkin's Lymphoma
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is determine if 2 cycles of SGN-35 can be used instead of ICE prior to autologous stem cell transplant (ASCT) for relapsed and refractory HL.
- Trial name
- NCT01508312
- Testing
- brentuximab vedotin (SGN-35)
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia, Myeloid, Chronic, AML
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
In this study our hypothesis is that infusion of donor lymphocyte immune cells from the subject's bone marrow donor will activate the subject's immune system to attack their cancer.
- Conditions
- Leukemia, Myeloid, Chronic, AML, MDS, Leukemia, Lymphocytic, Acute
- Trial name
- NCT00167167
- Testing
- Donor Lymphocyte Infusion
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphocytic, Acute, AML
Stem Cell Transplantation for Hematological Malignancies
This protocol using busulfan, cyclophosphamide and melphalan has been designed as conditioning therapy for patients receiving stem cell transplantation for acute leukemia or myelodysplastic syndrome (MDS).
- Conditions
- Leukemia, Lymphocytic, Acute, AML, MDS
- Trial name
- NCT00176839
- Testing
- Stem Cell Transplant, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Stem Cell Transplantation, Leukemia
Infusion of Expanded Cord Blood T Cells
The goal of this clinical research study is to learn if treating umbilical cord blood with growth factors before a transplant can help to improve the body's ability to accept the cord blood transplants.
- Conditions
- Stem Cell Transplantation, Leukemia, Lymphoma, Pediatric Disorders
- Trial name
- NCT00972101
- Testing
- Total Body Irradiation (TBI), Melphalan, Thiotepa
- Sponsor
- M.D. Anderson Cancer Center
Graft Versus Host Disease, Recurrent Adult Acute Lymphoblastic Leukemia
Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
This randomized phase III trial is studying low-dose prednisone or methylprednisolone to see how well they work compared with standard-dose prednisone or methylprednisolone in treating patients with newly diagnosed acute…
- Trial name
- NCT00929695
- Testing
- prednisone, methylprednisolone, questionnaire administration
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Fred Hutchinson Cancer Center
Mycoses, HIV Infections
A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections
To compare the safety, tolerance and efficacy of fluconazole and amphotericin B as treatment for biopsy proven fungal infections in major organs, disseminated infection, suspected fungal infection and fungemia in adult…
- Trial name
- NCT00002277
- Testing
- Fluconazole, Amphotericin B
- Where
- 3 sites in United States
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.